98%
921
2 minutes
20
Objectives: This study aimed to develop susceptible-exposed-infectious-recovered-vaccinated (SEIRV) models to examine the effects of vaccination on coronavirus disease 2019 (COVID-19) case trends in Malaysia during Phase 3 of the National COVID-19 Immunization Program amidst the Delta outbreak.
Methods: SEIRV models were developed and validated using COVID-19 case and vaccination data from the Ministry of Health, Malaysia, from June 21, 2021 to July 21, 2021 to generate forecasts of COVID-19 cases from July 22, 2021 to December 31, 2021. Three scenarios were examined to measure the effects of vaccination on COVID-19 case trends. Scenarios 1 and 2 represented the trends taking into account the earliest and latest possible times of achieving full vaccination for 80% of the adult population by October 31, 2021 and December 31, 2021, respectively. Scenario 3 described a scenario without vaccination for comparison.
Results: In scenario 1, forecasted cases peaked on August 28, 2021, which was close to the peak of observed cases on August 26, 2021. The observed peak was 20.27% higher than in scenario 1 and 10.37% lower than in scenario 2. The cumulative observed cases from July 22, 2021 to December 31, 2021 were 13.29% higher than in scenario 1 and 55.19% lower than in scenario 2. The daily COVID-19 case trends closely mirrored the forecast of COVID-19 cases in scenario 1 (best-case scenario).
Conclusions: Our study demonstrated that COVID-19 vaccination reduced COVID-19 case trends during the Delta outbreak. The compartmental models developed assisted in the management and control of the COVID-19 pandemic in Malaysia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10867513 | PMC |
http://dx.doi.org/10.4178/epih.e2023093 | DOI Listing |
J Clin Invest
September 2025
The University of Texas at Austin, Austin, United States of America.
Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.
Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
September 2025
School of Health & Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Clarice Pears Building, 90 Byres Road, G12 8TB, Glasgow, UK.
The rate of improvement in life expectancy and mortality slowed considerably in a number of high-income countries from the early 2010s, predating the COVID-19 pandemic by almost a decade. Evidence for different countries, including the separate nations of the United Kingdom (e.g.
View Article and Find Full Text PDFJ Refract Surg
September 2025
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Purpose: To report a case of acute and transient accommodative insufficiency after laser in situ keratomileusis (LASIK) due to coronavirus disease 2019 (COVID-19).
Methods: Case report and literature review.
Results: A 36-year-old man complained of acute blurred near vision 7 days after uneventful bilateral hyperopic LASIK, concurrent with the onset of COVID-19 infection.
Anaesthesia
September 2025
Department of Applied Health Sciences, School of Health Sciences, University of Birmingham, UK.
Introduction: Restoration of surgical capacity is essential to post-COVID-19 recovery. This study explored the use and safety of anaesthesia options for inguinal hernia surgery, a common tracer condition, to describe current global practice and highlight opportunities to build the capacity of health systems.
Methods: This is a secondary analysis of an international prospective cohort study of consecutive patients who underwent elective inguinal hernia surgery.
Clin Infect Dis
September 2025
Harvard Medical School, Boston, Massachusetts, USA.
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
View Article and Find Full Text PDF